Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...